In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Xenobiotica; the fate of foreign compounds in biological systems

• Publication date

  2017-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1080/00498254.2016.1203505PMID 27414183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs

  2017cited by this paper
• A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry.

  2016cited by this paper
• Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

  2016cited by this paper
• Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study

  2016cited by this paper
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

  2015cited by this paper
• Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

  2015cited by this paper
• Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).

  2012cited by this paper
• Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers.

  2012cited by this paper
• A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals

  2011cited by this paper
• Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438)

  2011cited by this paper
• A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.

  2011cited by this paper
• 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

  2010cited by this paper
• Acid peptic diseases: pharmacological approach to treatment

  2009influential reference
• Selective Role of Sulfotransferase 2A1 (SULT2A1) in the N-Sulfoconjugation of Quinolone Drugs in Humans

  2009cited by this paper
• Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT “Pie”

  2009cited by this paper
• New concepts of resistance in the treatment of Helicobacter pylori infections

  2008cited by this paper
• The Gastric H,K ATPase as a Drug Target: Past, Present, and Future

  2007influential reference
• Pharmacogenomics‐based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori

  2007cited by this paper
• CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.

  2007cited by this paper
• Review article: acid‐related disease – what are the unmet clinical needs?

  2006influential reference
• Human sulfotransferases and their role in chemical metabolism.

  2006cited by this paper
• Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

  2005cited by this paper
• AcmA of Lactococcus lactis is an N‐acetylglucosaminidase with an optimal number of LysM domains for proper functioning

  2005cited by this paper
• Pharmacogenetics of the Proton Pump Inhibitors: A Systematic Review

  2003cited by this paper
• Genetic "differences".

  2002cited by this paper
• Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

  2002cited by this paper
• Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations

  2001cited by this paper
• Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors

  1996influential reference
• Gastric (H+,K+)-ATPase.

  1986influential reference

• Vonoprazan-based triple therapy for Helicobacter pylori resistant to first-line regimens: A guideline-compliant 14-day multicenter study in Egypt.

  2025cites this paper
• Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis

  2025cites this paper
• Targeting Helicobacter pylori in liver-impaired populations: a systematic review of efficacy and safety

  2025cites this paper
• Efficacy and Safety of Vonoprazan and High‐Dose Amoxicillin Dual Therapy for Rescue Treatment of Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial

  2025cites this paper
• Vonoprazan: A Review in Erosive Esophagitis and Non-Erosive Gastro-Esophageal Reflux Disease

  2025cites this paper
• Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial

  2025cites this paper
• Bloqueadores ácidos competitivos de potasio (PCABs): estado del arte

  2025cites this paper
• Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?

  2025cites this paper
• The Impact of Vonoprazan on Tacrolimus Blood Levels in Transplant Recipients: A Systematic Review and Meta-Analysis

  2025cites this paper
• High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism among Patients with Gastroesophageal Reflux Disease.

  2025cites this paper
• Efficacy and safety of vonoprazan and high dose amoxicillin dual therapy in eradicating Helicobacter pylori: A systematic review and meta-analysis.

  2024cites this paper
• Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease

  2024cites this paper
• Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders.

  2024cites this paper
• In Vitro Metabolism and Transport Characteristics of Zastaprazan

  2024cites this paper
• Vonoprazan a novel potassium competitive acid blocker; another leap forward

  2024cites this paper
• Vonoprazan: A Review in Helicobacter pylori Infection

  2024cites this paper
• Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10‐Day Dual Therapy

  2024cites this paper
• Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling

  2023cites this paper
• Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo

  2023cites this paper
• Pilot studies of vonoprazan‐containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan

  2023cites this paper
• Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis

  2023cites this paper
• Potassium-competitive Acid Blocker: A Newer Target in the Treatment of Acid Peptic Disorder

  2023cites this paper
• Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept

  2022cites this paper
• Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders.

  2022cites this paper
• Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the US and Europe: Randomized Clinical Trial.

  2022cites this paper
• Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen

  2022cites this paper
• Identification, characterization, synthesis of major metabolites biotransformed from vonoprazan fumarate

  2022cites this paper
• Vonoprazan and high‐dose amoxicillin dual therapy for Helicobacter pylori first‐line eradication: A single‐arm, interventional study

  2022cites this paper
• The Effects of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Liver Transplant Recipients.

  2022cites this paper
• Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo

  2022cites this paper
• Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients

  2021influential citation
• Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders

  2021cites this paper
• Delay of endoscopic submucosal dissection-induced gastric ulcer healing by methotrexate

  2021cites this paper
• Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?

  2021cites this paper
• Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms.

  2021cites this paper
• The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan

  2021cites this paper
• A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure

  2021cites this paper
• Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis

  2020cites this paper
• DDDT_A_255427 2199..2206

  2020cites this paper
• Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y12 Assay in Patients With Coronary Artery Disease

  2020cites this paper
• Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection

  2020cites this paper
• Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection

  2020cites this paper
• Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy

  2020influential citation
• Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients.

  2020cites this paper
• The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection

  2020cites this paper
• Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats

  2020cites this paper
• Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo

  2020cites this paper
• Physiologically based pharmacokinetic–pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans

  2020cites this paper
• Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis

  2019cites this paper
• Efficacy of Vonoprazan for Helicobacter pylori Eradication

  2019cites this paper
• Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis

  2019cites this paper
• Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers

  2019cites this paper
• Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan

  2019cites this paper
• Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype

  2018influential citation
• In Vitro Assessment of Potential for CYP-Inhibition-Based Drug–Drug Interaction Between Vonoprazan and Clopidogrel

  2018cites this paper
• Arenobufagin is a novel isoform-specific probe for sensing human sulfotransferase 2A1

  2018cites this paper
• Effects of Vonoprazan Compared with Esomeprazole on the Healing of Artificial Postendoscopic Submucosal Dissection Ulcers: A Prospective, Multicenter, Two-Arm, Randomized Controlled Trial

  2018influential citation
• Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test

  2018cites this paper
• Vonoprazan fumarate for the management of acid-related diseases

  2017cites this paper
• Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis

  2017cites this paper
• Letter: CYP3A4/5 genotype status and outcome of vonoprazan‐containing Helicobacter pylori eradication therapy in Japan

  2017cites this paper
• Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs

  2017cites this paper
• Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry.

  2017cites this paper
• Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors

  2017cites this paper
• Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study

  2016cites this paper
• Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men

  2016cites this paper